Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Other Non-Current Liabilities (2016 - 2021)

Historic Other Non-Current Liabilities for Cardiff Oncology (CRDF) over the last 12 years, with Q3 2021 value amounting to $30000.0.

  • Cardiff Oncology's Other Non-Current Liabilities fell 8422.7% to $30000.0 in Q3 2021 from the same period last year, while for Sep 2021 it was $30000.0, marking a year-over-year decrease of 8422.7%. This contributed to the annual value of $285000.0 for FY2020, which is 12201.79% up from last year.
  • Per Cardiff Oncology's latest filing, its Other Non-Current Liabilities stood at $30000.0 for Q3 2021, which was down 8422.7% from $214000.0 recorded in Q2 2021.
  • In the past 5 years, Cardiff Oncology's Other Non-Current Liabilities registered a high of $2.0 million during Q3 2017, and its lowest value of $4956.0 during Q3 2019.
  • For the 5-year period, Cardiff Oncology's Other Non-Current Liabilities averaged around $294331.4, with its median value being $139044.0 (2020).
  • Per our database at Business Quant, Cardiff Oncology's Other Non-Current Liabilities crashed by 9654.77% in 2018 and then surged by 373775.22% in 2020.
  • Quarter analysis of 5 years shows Cardiff Oncology's Other Non-Current Liabilities stood at $649387.0 in 2017, then tumbled by 93.53% to $42000.0 in 2018, then surged by 205.64% to $128368.0 in 2019, then skyrocketed by 122.02% to $285000.0 in 2020, then tumbled by 89.47% to $30000.0 in 2021.
  • Its Other Non-Current Liabilities was $30000.0 in Q3 2021, compared to $214000.0 in Q2 2021 and $191000.0 in Q1 2021.